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Abstract Two important explanations exist for cross-border reproductive care: restrictive legislation at home and limited access to
affordable treatment. Both have recently been subject to patient pressure, favouring domestic and not cross-border services. The
oppressive effect of regulation has been best illustrated in Italy, where legislation introduced as Law 40 in 2004 imposed restric-
tions on embryo freezing and embryo selection. After a decade of legal challenges by patients, the components of Law 40 have now
been deemed unconstitutional in Italy. Similarly, a paucity of donor gametes in the UK has left many patients with few options but
to seek donors and treatments overseas. Yet new techniques of donor recruitment and a revised allowance of compensation now
means that some UK clinics can meet all requirements for donor gametes and patient matching from their own resources.
© 2015 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.
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Introduction
In a recent paper in Reproductive Biomedicine Online,
Benagiano et al. (2014) considered the legal ruling in Italy,
which in April 2014 withdrew the national ban on gamete do-
nation. The restrictions had been imposed in 2004 when Italy’s
infamous Law 40 had been introduced to bring some form of
regulation to a country, which until then had been de-
scribed as the ‘wild west’ of reproductive medicine. Also pro-
scribed in this draconian legislation were embryo freezing,
pre-implantation genetic diagnosis (PGD) and the fertiliza-
tion of more than three oocytes in a given treatment cycle
combined with the compulsory transfer of all the resulting
embryos.
Reversal of Law 40 in Italy
Law 40 was to have immediate catastrophic effects on as-
sisted reproduction techniques in Italy. Mean pregnancy rate
per transfer declined and the rate of multiple pregnancies in-
creased (Benagiano et al., 2014). Overnight, there was an
exodus of Italian fertility patients looking for appropriate treat-
ments overseas. Italy would be transformed from a net im-
porter of reproductive tourists to a net exporter, as patients
turned to Spain, Slovenia, Ukraine and other overseas des-
tinations in search of PGD, gamete donation or even routine
IVF and intracytolasmic injection (ICSI) if patients wanted to
avoid the likelihood of multiple pregnancies. In one of the few
studies of this 21st century phenomenon, The European Society
of Human Reproduction and Embryology (ESHRE)’s Task Force
on Cross-Border Reproductive Care found that patients from
Italy made up the greatest proportion of patients (31.8%) vis-
iting clinics in six European countries and that ‘legal reasons
were predominant’ (Shenﬁeld et al., 2010).
It has now taken 10 years and several constitutional and
local challenges to dismantle many of the legislative com-
ponents of Law 40. Indeed, in 2012, the European Court of
Human Rights ruled that Italy’s ban on embryo screening [by
PGD] breached two articles of the European Convention of
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Human Rights, including the right to respect for family and
private life. The ruling followed the challenge of an Italian
couple whose ﬁrst child had died from cystic ﬁbrosis
(Benagiano et al., 2014).
It is signiﬁcant, as Benagiano et al. (2014) note, that these
challenges came not from doctors but from patients. Signiﬁ-
cant too is that all the legal rulings to withdraw the restric-
tions were made in the interests of patients and their rights
– to have children, to ‘self-determination’, and to health. At
the practical level, the consequence now is that desperate
Italian patients need no longer be forced to travel to over-
seas destinations for donor eggs or other forms of previ-
ously forbidden treatments, unless they choose to do so for
personal reasons. Italy, thanks to the perseverance and jus-
tiﬁable self-interest shown by its patients, can oncemore prac-
tise its reproductive medicine on a playing ﬁeld which is now
deemed to be more level.
Cross-border travel, public pressure and donor
compensation
One other explanation for the trend in crossing borders, iden-
tiﬁed by the ESHRE study, was to gain ‘better access to treat-
ment than in the country of origin’, an objective also
highlighted in a comprehensive symposium reported in this
journal in 2011 (Gürtin and Inhorn, 2011). The question of
better access, the ESHRE investigators suggested, ‘may also
be linked to the regulatory limits of compensation to donors’,
and they noted at the time of their study (in 2010) that the
UK allowed very limited compensation to both egg and sperm
donors. By contrast, Spain was reported to be paying its egg
donors around 900 Euros per cycle, and the Czech Republic
around 500 Euros. It was for these reasons of discrepancy in
supply, long waiting lists at home and cross-border trafﬁc to
Spain and elsewhere that the UK’s Human Fertilization and
Embryology Authority (HFEA) announced a public consulta-
tion in 2011 to address the problems inherent in the UK’s
limited provision of gamete donation. The perennial ques-
tion of appropriate payments to gamete donors had already
been the subject of three previous public consultations
between 1997 and 2009 (Human Fertilisation and Embryology
Authority, 2011). The aim this time, said the HFEA, was to
‘focus on what it meant to people – to those born of as-
sisted reproduction, to donors, to patients wanting desper-
ately to have a baby and to the public in general’. Independent
public and patient consultations on the subject were also con-
ducted by The Nufﬁeld Council on Bioethics (2011) and other
academic institutions (Gürtin and Inhorn, 2011). After con-
sidering the evidence, the HFEA in April 2012 raised com-
pensation to £35 ‘per visit’ for sperm donors, and to £750 per
cycle for oocyte donors; the revised fees, said the HFEA, should
be viewed ‘not in terms of crude sums but in terms of the value
of donation’.
Reversal of donor gamete shortages in the UK
Our own ﬁgures from the London Women’s Clinic in London
(and its afﬁliated London Egg Bank) suggest that the revised
policy introduced by the HFEA is now beginning to have a ben-
eﬁcial effect on egg donation trends and ﬁnally bringing some
relief to the former chronic shortages. During the period
January 2013 to July 2014, for example, eggs were col-
lected from 220 registered non-patient donors, which was 10
times the number of non-patient egg donors we had re-
cruited in any of the previous 2 years (unpublished data). This
resulted in 222 completed recipient treatments (with a single
attempt pregnancy rate of 59% per recipient). Surplus embryos
when available were vitriﬁed and stored for future use in 75%
of recipients. Such ﬁgures, although satisfactory in terms of
success and volume, remain far below those recorded by some
Spanish clinics: at the 2014 Annual Meeting of ESHRE, Cobo
reported that, in 2013 alone, 946 donors at IVI Valencia had
vitriﬁed 10,690 oocytes for the egg bank, and that, since vit-
riﬁcation had been introduced for egg banking, more than
50,000 oocytes had been warmed for use in 4907 cycles (See
http://www.eshre2014.eu/Media/Press-conference-schedule/
Ana-Cobo.aspx). Nevertheless, at our own clinic in London,
we are now able to meet the demand (and matching prefer-
ences) of all patients requiring egg donation. None are forced
to travel abroad or face long waiting lists at our clinic, which
was the case before April 2012 when, in the absence of com-
pensation, egg sharers (i.e. patient donors seeking reduced
fee treatment in return for donating a proportion of their eggs)
were the predominant source of donor eggs (Ahuja et al., 2000;
Ahuja, 2012; Human Fertilisation and Embryology Authority,
2014).
Similarly, sperm donation is progressively non-reliant on
the ‘Viking invasion’ of donor sperm (sperm imported to the
UK from Danish banks), as some have claimed in describing
shortages in the UK (http://www.bbc.co.uk/programmes/
b04hvxb5). The latest ﬁgures from the HFEA for 2010 record
that 24% of all registered sperm donors were from ‘over-
seas’, which has prompted some commentators to warn that
‘this was limiting patient choice and increasing waiting times’
(see http://www.hfea.gov.uk/3412.html). Although this was
true in the past, again it has not been the case recently at
our own clinic. As early as 2011 at our own sperm bank
(www.londonspermbank.com), we demonstrated that a pro-
gramme reliant on good communication and personalized cus-
tomer care could generate a signiﬁcant increase in donors
(Bahadur et al., 2011). In the past 3 years, this trend has es-
calated to such levels that demographically the outcome now
provides a far wider range of donors from all walks of life than
ever seen before. Despite an increasing demand for donor
sperm, we have been able to meet all our patient requests
for donor matching online and have completed over 5000 treat-
ments since 2010. Patients can now access donor sperm from
a regulated sperm bank and check donor characteristics from
an online platform, rather than depend on unlicensed private
donations or on supplies from abroad. Our own efforts would
be greatly supported by the popular announcements in August
2014 of a national sperm bank in the UK run by the National
Gamete Donation Trust and Birmingham Women’s Hospital to
provide a supply of donor sperm to UK patients without re-
liance on overseas sources (Byrne, 2014).
The most recent UK analysis of the availability of gamete
donors provides further support for this trend (Table 1). The
results published by the HFEA show over 50% growth over 5
years in the availability of non-patient gamete donors in the
UK (Human Fertilisation and Embryology Authority, 2014). The
HFEA attributed this signiﬁcant increase in registered donors
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to the increased level of compensation, increased aware-
ness and marketing. As the regulations require all UK gamete
donors to be traceable to children when they reach the age
of 18 years, it is a justiﬁable expectation that, in future, fewer
UK couples will travel overseas for treatment except those
who prefer anonymous gamete donors. Conversely, the re-
laxation of rules in the UK and traceability requirements may
encourage some overseas patients to attend licensed UK clinics
for treatment.
Internet and harmonization of anomalous
policies in Europe
The key to this rise in the domestic supply of donor gametes
and the associated anticipated decrease in patients travel-
ling abroad has of course been the Internet (Speier, 2011).
It goes without saying that patients will not consider jour-
neying abroad if availability and access are buoyant at home.
Online catalogues of donors, social media communication and
relevant patient information (waiting times, treatment costs,
live birth rates) will all support a patient-focused approach
driven by the Internet. Just as online access to clinics made
patients better informed about the relative availability and
costs of treatment abroad, so it is now enabling the greater
choices available to patients at home. Why would UK pa-
tients, for example, pay $30,000 in a ‘shared-risk’ egg do-
nation programme in the USA (see http://www.washingtonpost
.com/national/health-science/some-infertility-programs-
offer-money-back-guarantees-conception-may-cost-30000/
2014/09/15/9fee34ee-384e-11e4-9c9f-ebb47272e40e_story
.html), when comparable treatments (and outcomes) can be
easily found at much lower cost at home? The successful use
of vitriﬁcation technology in oocyte storage also means that,
instead of women travelling to the source of donor eggs in
different countries, frozen eggs with desirable phenotypes can
be quite legally made available nearer to where they live.
The ‘good practice guide for cross-border reproductive
care’ by ESHRE deﬁned the practice as a ‘solution’ to the
anomalies found in reproductive medicine (Shenﬁeld et al.,
2011). Such anomalies exist in legislation, regulation, access,
availability, waiting times and costs. Cross-border care in re-
production can circumvent these anomalies and provide au-
tonomy and equity to patients where before there was little
(Storrow, 2010). And this too conforms with the European
Union’s directive of 2011 on the application of patient rights
in all cross-border healthcare and the free movement of goods,
persons and services throughout the Union (http://eurlex
.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2011:088:
0045:0065:EN:PDF).
The ESHRE guide, however, also claims that the ideal situ-
ation is not cross-border care but ‘fair access at home for all
patients’, and it is a movement in this direction, I suggest,
which we are now seeing in the harmonization of strategies
in donor recruitment and the provision of treatment options
in Europe. For just as the phenomenon of cross-border re-
productive care was a popular response to restrictive legis-
lation or excessive waiting lists, so popular patient pressure
is also the agent to address these very anomalies at home and
remove the imbalances which favoured treatment overseas
– whether Law 40 in Italy or a shortage of gamete donors in
the UK. Other recent (all in September 2014) announce-
ments that promote harmonization within the EU include the
availability of IVF to single mothers in Sweden (http://
www.thelocal.se/20140925/regional-backing-for-ivf-for-singles),
the discontinuation of anonymous sperm donation in Ireland
(O’Loughlin, 2014) and the adoption in France by same sex
parents of IVF children conceived overseas (Brooks, 2014). All
of these decisions have been the result of persistent patient
pressure and media interest in the subject and collectively
they are all likely to reduce rather than increase the level of
cross-boarder reproductive care. Of course, the playing ﬁeld
is not yet level throughout Europe, nor will legislation ever
make it so, with the EU committed to the freedom of each
Member State ‘ to decide what type of healthcare it consid-
ers appropriate’. (http://eurlex.europa.eu/LexUriServ/
LexUriServ.do?uri=OJ:L:2011:088:0045:0065:EN:PDF). So
lesbian couples from France will still beat a path to Belgium
for donor insemination, carriers of a monogenic disease or
women with poor ovarian reserve in Germany still turn else-
where for PGD and egg donation, respectively. But there are
signs that the reasons for travelling are becoming fewer and
that the tide of cross-border reproductive care is at last be-
ginning to turn.
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